Summit Therapeutics plc Stock
-
Your prediction
Pros and Cons of Summit Therapeutics plc in the next few years
Pros
Cons
Performance of Summit Therapeutics plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Summit Therapeutics plc | - | - | - | - | - | - | - |
| Proteome Sciences | -37.210% | -35.714% | 3.846% | -27.027% | -53.448% | -59.091% | -49.057% |
| Oxford BioMedica PLC | -2.780% | 0.719% | 4.478% | 41.129% | 37.255% | 67.464% | -25.840% |
| Sareum Holdings plc | -0.760% | -0.758% | -7.092% | -56.333% | -56.623% | -83.625% | - |
News
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run
Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over
Why a $27 Million Buy Signals New Confidence in Weatherford Stock
Summit Street Capital Management established a new position in Weatherford International (NASDAQ:WFRD), adding 398,661 shares valued at an estimated $27.3 million during the third quarter, according
Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?
On November 14, New York City-based Summit Street Capital Management disclosed a new position in Signet Jewelers (NYSE:SIG), acquiring 264,054 shares valued at $25.3 million, according to its latest


